CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction AIM2-driven inflammasome activation in heart failure The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure

Original Research2021 Jan 12;S0828-282X(21)00005-2.

JOURNAL:Can J Cardiol. Article Link

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease

E O'Meara, S Verma. Keywords: SGLT2 inhibitors; heart failure; chronic kidney disease

Full Text PDF